Controlled trial of D-penicillamine in rheumatoid arthritis. Dose effect and the role of zinc

The findings are reported of a controlled clinical trial comparing in 66 rheumatoid arthritis patients 0 g (placebo), and 0.50 g a day and 1 g a day of penicillamine. Each of these groups has been subdivided into two, one part receiving 5 mg a day of zinc metal supplement, the other a placebo. The t...

Full description

Saved in:
Bibliographic Details
Published inScandinavian journal of rheumatology Vol. 5; no. 4; p. 241
Main Authors Mery, C, Delrieu, F, Ghozlan, R, Saporta, L, Simon, F, Amor, B, Menkes, C J, Delbarre, F
Format Journal Article
LanguageEnglish
Published England 1976
Subjects
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - metabolism
Clinical Trials as Topic
Drug Evaluation
Drug Therapy, Combination
Female
Humans
Leukocyte Count
Male
Middle Aged
Penicillamine - administration & dosage
Penicillamine - adverse effects
Penicillamine - therapeutic use
Placebos
Zinc - metabolism
Zinc - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:The findings are reported of a controlled clinical trial comparing in 66 rheumatoid arthritis patients 0 g (placebo), and 0.50 g a day and 1 g a day of penicillamine. Each of these groups has been subdivided into two, one part receiving 5 mg a day of zinc metal supplement, the other a placebo. The trial was planned to be double-blind, and for each patient to take part for 4 months. The results prove the effectiveness of penicillamine in rheumatoid arthritis. 0.50 g a day has the same effect as 1 g a day but gives less side effects. Zinc supplement inhibits the clinical effects of penicillamine but does not prevent the side effects.
ISSN:0300-9742
DOI:10.3109/03009747609099913